Apontis Pharma AG (XTER:APPH) COGS-to-Revenue : 0.46 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Apontis Pharma AG COGS-to-Revenue?

Apontis Pharma AG's Cost of Goods Sold for the six months ended in Dec. 2024 was €11.90 Mil. Its Revenue for the six months ended in Dec. 2024 was €25.74 Mil.

Apontis Pharma AG's COGS to Revenue for the six months ended in Dec. 2024 was 0.46.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Apontis Pharma AG's Gross Margin % for the six months ended in Dec. 2024 was 53.77%.

Apontis Pharma AG COGS-to-Revenue Historical Data

The historical data trend for Apontis Pharma AG's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apontis Pharma AG COGS-to-Revenue Chart

Apontis Pharma AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.36

0.34

0.37

0.43

Apontis Pharma AG Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial							0.36	0.36	0.38	0.39	0.46

Apontis Pharma AG COGS-to-Revenue Calculation

Apontis Pharma AG's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	20.765	/	48.467
	=	0.43

Apontis Pharma AG's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	11.9	/	25.741
	=	0.46

Apontis Pharma AG (XTER:APPH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Apontis Pharma AG's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	11.9 / 25.741
	=	53.77 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Apontis Pharma AG COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Apontis Pharma AG's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Apontis Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rolf-Schwarz-Schutte-Platz 1, Monheim, BY, DEU, 40789

Website

https://www.apontis-pharma.de

Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.

Executives

Bruno Wohlschlegel	Board of Directors
Thomas Milz	Board of Directors
Thomas Zimmermann	Chief Financial Officer
Karlheinz Gast	Board of Directors

Apontis Pharma AG Headlines

No Headlines